{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-22-001896","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.106969+00:00","generated_at":"2026-06-25T18:15:36.434670+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Chemomab Q1 net loss $5.1M; cash $57.5M; advancing CM-101 in PSC and SSc","bullets":["Net loss of $5.1M ($0.02 per share) vs $1.7M in Q1 2021; R&D expenses $2.7M, G&A $2.6M (incl $0.9M stock comp).","Cash and equivalents $57.5M at March 31, 2022, down from $61.2M at Dec 31, 2021.","Completed enrollment in Phase 2 liver fibrosis study; interim PSC readout expected late 2022; SSc Phase 2 launch planned by year-end.","Appointed Jack Lawler as VP of Global Clinical Development Operations.","Presented CCL24 data at SSc congress; findings support CM-101's role in fibrosis and endothelial damage."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-22-001896","json":"https://secwatch.observer/filing/0001178913-22-001896.json","markdown":"https://secwatch.observer/filing/0001178913-22-001896.md","text":"https://secwatch.observer/filing/0001178913-22-001896.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001896/0001178913-22-001896-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001896/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:15:36.434670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}